BW LPG Limited – Financial Results for Q3 2025

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited: Highlights Q3 2025 Q3 2025 profit: Q3 2025 profit attributable to…

BW LPG Limited – Key Information Relating to the Cash Dividend for Q3 2025

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker…

TotalEnergies, TES, Osaka Gas, Toho Gas and ITOCHU Partner Up to Develop the Live Oak Project for e-NG Production in Nebraska

PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE), TES, Osaka Gas, Toho Gas, and ITOCHU have signed a…

Tech Leaders Brace for 2026: Security, Connectivity and Data Sovereignty at Stake, According to Expereo

LONDON--(BUSINESS WIRE)--2025 has been a transformative year for global technology. Rapid deployment of advanced connectivity…

P.I. Works Drives Stronger Network Results for Beeline Uzbekistan

ISTANBUL--(BUSINESS WIRE)--P.I. Works celebrates the success of its long-time client Beeline Uzbekistan, recognized by independent…

Hanshow Achieves SOC 2 Type II and SOC 3 Certifications, Elevating Data Security Standards for Global Retailers

SHANGHAI--(BUSINESS WIRE)--Hanshow, a global leader in digital retail solutions, announced that its All-Star digital solution…

Netcracker Completes Revenue Management Modernization for SLT-MOBITEL

Leading Asian Operator Leverages Advanced Features of Netcracker Digital BSS Along With Multi-Year Support Services…

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

BANGALORE, India--(BUSINESS WIRE)--#AurigeneOncology--Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today…

Development Bank of Japan and Chiyoda Invest in Heirloom

Strategic investments position Heirloom for participation in Japan's emerging carbon market BRISBANE, Calif.--(BUSINESS WIRE)--Heirloom, America's…

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at…